Planned intervention: On Wednesday June 26th 05:30 UTC Zenodo will be unavailable for 10-20 minutes to perform a storage cluster upgrade.
Published March 31, 2020 | Version v1
Dataset Open

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches

Description

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease.

Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers.  

In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients.  However, a lot of improvement is needed given the disappointing results obtained so far.

Files

Files (94.5 kB)

Name Size Download all
md5:d70e72b894a82f924b670b16a82afc0f
94.5 kB Download

Additional details

Related works

Is cited by
Journal article: 10.1016/j.canlet.2019.12.029 (DOI)

Funding

HEPAVAC – Cancer Vaccine development for Hepatocellular Carcinoma 602893
European Commission

Subjects

PUBLICATION
10.1016/j.canlet.2019.12.029